Payment overview · 2025
General Payments
$79.42
5 reported records · 3 companies
Healthcare provider profile · identity verified
Levi Thomas Mcdaniel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MAYWOOD, IL · NPI 1568705333
Verified facts
What the public records show
CMS Open Payments records show Levi Thomas Mcdaniel, M.D. received $79.42 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 65.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.68 | 65.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.06 | 17.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.68 | 17.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.42 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.68 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 306 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
306 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 719 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 520 | 122 |
| Lisinopril | Lisinopril | 443 | 108 |
| Losartan Potassium | Losartan Potassium | 410 | 96 |
| Omeprazole | Omeprazole | 376 | 89 |
| Gabapentin | Gabapentin | 373 | 66 |
| Metformin Hcl | Metformin Hcl | 332 | 78 |
| Furosemide | Furosemide | 320 | 67 |
| Eliquis | Apixaban | 306 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 271 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 54 |
| Potassium Chloride | Potassium Chloride | 230 | 35 |
| Jardiance | Empagliflozin | 218 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 51 |
| Tramadol Hcl | Tramadol Hcl | 168 | 39 |
| Alprazolam | Alprazolam | 161 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 30 |
| Carvedilol | Carvedilol | 143 | 33 |
| Sertraline Hcl | Sertraline Hcl | 139 | 28 |
| Montelukast Sodium | Montelukast Sodium | 136 | 38 |
| Meloxicam | Meloxicam | 135 | 42 |
| Januvia | Sitagliptin Phosphate | 132 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 25 |
| Allopurinol | Allopurinol | 119 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 32 |
| Lorazepam | Lorazepam | 115 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 34 |
| Ozempic | Semaglutide | 108 | 19 |
| Prednisone | Prednisone | 108 | 38 |
| Finasteride | Finasteride | 107 | 19 |
| Donepezil Hcl | Donepezil Hcl | 106 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 18 |
| Simvastatin | Simvastatin | 84 | 19 |
| Trulicity | Dulaglutide | 81 | 11 |
| Pregabalin | Pregabalin | 79 | 14 |
| Azithromycin | Azithromycin | 78 | 69 |
| Methylprednisolone | Methylprednisolone | 78 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 12 |
| Clonazepam | Clonazepam | 77 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 13 |
| Lovastatin | Lovastatin | 74 | 15 |
| Mirtazapine | Mirtazapine | 72 | 11 |
| Metformin Hcl Er | Metformin Hcl | 69 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 14 |
| Warfarin Sodium | Warfarin Sodium | 65 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 64 | suppressed |
| Spironolactone | Spironolactone | 64 | 18 |
| Ondansetron Odt | Ondansetron | 63 | 20 |
| Memantine Hcl | Memantine Hcl | 62 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 61 | suppressed |
| Novolog Flexpen | Insulin Aspart | 61 | suppressed |
| Klor-Con M20 | Potassium Chloride | 60 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 12 |
| Famotidine | Famotidine | 58 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 47 |
| Ezetimibe | Ezetimibe | 55 | 14 |
| Atenolol | Atenolol | 54 | suppressed |
| Glimepiride | Glimepiride | 54 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Glipizide | Glipizide | 50 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 45 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 16 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 33 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 27 |
| Alendronate Sodium | Alendronate Sodium | 40 | 12 |
| Metolazone | Metolazone | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 15 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 11 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 28 |
| Clonidine Hcl | Clonidine Hcl | 36 | 12 |
| Fluconazole | Fluconazole | 36 | 17 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 17 |
| Primidone | Primidone | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Nystatin | Nystatin | 28 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Sulfasalazine | Sulfasalazine | 24 | suppressed |
| Budesonide | Budesonide | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 11 |
| Brilinta | Ticagrelor | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Amoxapine | Amoxapine | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.42 · 5 records | ABBVIE INC. | ELIQUIS, NURTEC ODT, QULIPTA, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error